Moreover, the overall survival of NPC patients with high expression of both ZIC2 and JUNB or both ZIC2 and CD163 was significantly shorter than that of patients with low expression of both ZIC2 and JUNB or both ZIC2 and CD163 (p = 0.004, p = 0.013) (Fig. 6G–I). This evidence concerns the gene ZIC2 and nasopharyngeal carcinoma.